The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages (SMAs).

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

This is to inform you that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India, to import and distribute Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi), according to a stock exchange filing.

AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I think AZN stock is a compelling buy.

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.